ARA-290 (Cibinetide)

A small peptide based on EPO that calms inflammation. Tested for nerve pain without EPO's blood-thickening effect.

Evidence: Limited human research
Half-life: Short
Sources: 2 cited

Is ARA-290 (Cibinetide) FDA-approved?

Investigational. Not FDA-approved.

Overview

ARA-290 copies a small part of erythropoietin (EPO) that switches on a tissue-protective receptor but not the one that makes red blood cells. In a small 4-week trial in people with sarcoidosis and nerve pain, it improved neuropathy symptoms compared with placebo, and a follow-up study found more small nerve fibers in the cornea.

How it works

It activates the "innate repair receptor," which dampens inflammation and protects stressed tissue.

How long does ARA-290 (Cibinetide) stay in the body?

Short; not well established.

What it's studied for

Small fiber neuropathy and nerve pain
Diabetic complications

Related: TB-500, Semax, BPC-157, Selank.

Sources

The studies and prescribing labels this page is written from.

Safety and efficacy of ARA 290 in sarcoidosis patients with small fiber neuropathy. Mol Med, 2012 PubMed
Cibinetide Improves Corneal Nerve Fiber Abundance in Sarcoidosis-Associated Small Nerve Fiber Loss. Invest Ophthalmol Vis Sci, 2017 PubMed